Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Targeting JNK3 for the treatment of neurodegenerative disorders.

Resnick L, Fennell M.

Drug Discov Today. 2004 Nov 1;9(21):932-9. Review.

PMID:
15501728
2.

JNK3 as a therapeutic target for neurodegenerative diseases.

Antoniou X, Falconi M, Di Marino D, Borsello T.

J Alzheimers Dis. 2011;24(4):633-42. doi: 10.3233/JAD-2011-091567. Review.

PMID:
21321401
3.

Targeting the JNK pathway for therapeutic benefit in CNS disease.

Bozyczko-Coyne D, Saporito MS, Hudkins RL.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):31-49. Review.

PMID:
12769633
4.

Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases.

Saporito MS, Hudkins RL, Maroney AC.

Prog Med Chem. 2002;40:23-62. Review.

PMID:
12516522
5.

JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.

Mehan S, Meena H, Sharma D, Sankhla R.

J Mol Neurosci. 2011 Mar;43(3):376-90. doi: 10.1007/s12031-010-9454-6. Epub 2010 Sep 28. Review.

PMID:
20878262
6.

JNK signalling: a possible target to prevent neurodegeneration.

Borsello T, Forloni G.

Curr Pharm Des. 2007;13(18):1875-86. Review.

PMID:
17584114
7.

JNK inhibition as a potential strategy in treating Parkinson's disease.

Wang W, Ma C, Mao Z, Li M.

Drug News Perspect. 2004 Dec;17(10):646-54. Review.

PMID:
15696229
8.

The interleukin-1 system: an attractive and viable therapeutic target in neurodegenerative disease.

Allan SM, Pinteaux E.

Curr Drug Targets CNS Neurol Disord. 2003 Oct;2(5):293-302. Review.

PMID:
14529361
9.

Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy.

Kuan CY, Burke RE.

Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):63-7. Review.

PMID:
15723614
10.
11.

Ubiquitin proteasome system as a pharmacological target in neurodegeneration.

Hol EM, Fischer DF, Ovaa H, Scheper W.

Expert Rev Neurother. 2006 Sep;6(9):1337-47. Review.

PMID:
17009921
12.

Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.

Barchet TM, Amiji MM.

Expert Opin Drug Deliv. 2009 Mar;6(3):211-25. doi: 10.1517/17425240902758188. Review.

PMID:
19290842
13.

Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.

Hoffner G, André W, Vanhoutteghem A, Souès S, Djian P.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):217-31. Review.

PMID:
19811443
14.

Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium.

Camins A, Crespo-Biel N, Junyent F, Verdaguer E, Canudas AM, Pallàs M.

Curr Drug Metab. 2009 Jun;10(5):433-47. Review.

PMID:
19689241
15.

Nanotechnological applications for the treatment of neurodegenerative disorders.

Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D.

Prog Neurobiol. 2009 Aug;88(4):272-85. doi: 10.1016/j.pneurobio.2009.05.002. Epub 2009 May 30. Review.

PMID:
19486920
16.
17.

Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.

Perez DI, Gil C, Martinez A.

Med Res Rev. 2011 Nov;31(6):924-54. doi: 10.1002/med.20207. Epub 2010 Jun 23. Review.

PMID:
20577972
18.
19.
20.

The many roles of chemokine receptors in neurodegenerative disorders: emerging new therapeutical strategies.

Mines M, Ding Y, Fan GH.

Curr Med Chem. 2007;14(23):2456-70. Review.

PMID:
17979699
Items per page

Supplemental Content

Write to the Help Desk